Pre-made Befovacimab benchmark antibody ( Whole mAb, anti-TFPI therapeutic antibody, Anti-EPI/LACI/TFI Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Befovacimab biosimilar, Whole mAb, Anti-TFPI Antibody: Anti-EPI/LACI/TFI therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Befovacimab (formerly BAY 1093884) is an anti-tissue factor pathway inhibitor (anti-TFPI) antibody being developed by Bayer for the treatment of haemophilia.
| Products Name (INN Index) | Pre-Made Befovacimab biosimilar, Whole mAb, Anti-TFPI Antibody: Anti-EPI/LACI/TFI therapeutic antibody |
|---|---|
| INN Name | Befovacimab |
| Target | TFPI |
| Format | Whole mAb |
| Derivation | NA |
| Species Reactivity | Human |
| CH1 Isotype | IgG2 |
| VD LC | Lambda |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2019 |
| Year Recommended | 2020 |
| Companies | NA |
| Conditions Approved | NA |
| Conditions Active | Haemophilia |
| Conditions Discontinued | NA |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | TFPI |
| Package |
